Biopharma

관련학술자료

번호 제목 작성일
21 Intratumoral tavokinogene telseplasmid induces abscopal clinical responses in metastatic melanoma patients(Melanoma Bridge) 2018. 12. 26
20 KEYNOTE 695 TAVO Phase 2b Melanoma Trial Preliminary Data for SITC 2018 2018. 12. 26
19 Intratumoral tavokinogene telseplasmid and electroporation on in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (SABCS) 2018. 12. 26
18 Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1SITC 2017 2018. 09. 10
17 Intratumoral Administration Of A Multigene Construct By Electroporation Can Effectively Modulate Anti-Tumor Response In A Murine B16.f10 Model 2018. 09. 10
16 Clinical Immune Monitoring and Biomarker Data of TAVO Monotherapy Compared to TAVO with Pembrolizumab in Metastatic Melanoma Supports the Rationale for Combination Therapy 2018. 09. 10
15 Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response 2018. 09. 10
14 Intratumoral Electroporation-Mediated IL-12 Gene Therapy can Enhance Tumor Immunogenicity 2018. 09. 10
13 Immune Monitoring Outcomes of Patients with Stage III/IV Melanoma Treated with a Combination of Pembrolizumab and Intratumoral Plasmid Interleukin 12 (pIL-12) 2018. 09. 10
12 Phase II Study of Intratumoral Plasmid Interleukin 12 (pIL-12) with Electroporation 2018. 09. 10
11 Intratumoral IL-12 Therapy in HNSCC 2018. 09. 10
10 A Novel Applicator for Endoscopic Gene Electro-Transfer 2018. 09. 10